CorMedix Stock Based Compensation To Revenue from 2010 to 2024
| CRMD Stock | USD 8.57 0.30 3.38% |
Stock Based Compensation To Revenue | First Reported 2010-12-31 | Previous Quarter 71.55 | Current Value 90.23 | Quarterly Volatility 295.98703915 |
Check CorMedix financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CorMedix's main balance sheet or income statement drivers, such as Interest Expense of 32.6 K, Selling General Administrative of 37.6 M or Research Development of 10.2 M, as well as many indicators such as Price To Sales Ratio of 1.6 K, Dividend Yield of 0.0179 or PTB Ratio of 2.87. CorMedix financial statements analysis is a perfect complement when working with CorMedix Valuation or Volatility modules.
CorMedix | Stock Based Compensation To Revenue |
Latest CorMedix's Stock Based Compensation To Revenue Growth Pattern
Below is the plot of the Stock Based Compensation To Revenue of CorMedix over the last few years. It is a metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards. CorMedix's Stock Based Compensation To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CorMedix's overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation To Revenue | 10 Years Trend |
|
Stock Based Compensation To Revenue |
| Timeline |
CorMedix Stock Based Compensation To Revenue Regression Statistics
| Arithmetic Mean | 199.92 | |
| Geometric Mean | 42.49 | |
| Coefficient Of Variation | 148.05 | |
| Mean Deviation | 251.90 | |
| Median | 26.41 | |
| Standard Deviation | 295.99 | |
| Sample Variance | 87,608 | |
| Range | 670 | |
| R-Value | (0.72) | |
| Mean Square Error | 45,522 | |
| R-Squared | 0.52 | |
| Significance | 0 | |
| Slope | (47.61) | |
| Total Sum of Squares | 1.2M |
CorMedix Stock Based Compensation To Revenue History
About CorMedix Financial Statements
CorMedix stakeholders use historical fundamental indicators, such as CorMedix's Stock Based Compensation To Revenue, to determine how well the company is positioned to perform in the future. Although CorMedix investors may analyze each financial statement separately, they are all interrelated. For example, changes in CorMedix's assets and liabilities are reflected in the revenues and expenses on CorMedix's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in CorMedix. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Stock Based Compensation To Revenue | 71.55 | 90.23 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CorMedix is a strong investment it is important to analyze CorMedix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CorMedix's future performance. For an informed investment choice regarding CorMedix Stock, refer to the following important reports:Check out the analysis of CorMedix Correlation against competitors. For information on how to trade CorMedix Stock refer to our How to Trade CorMedix Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CorMedix. If investors know CorMedix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CorMedix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.80) | Revenue Per Share 0.212 | Quarterly Revenue Growth (0.47) | Return On Assets (0.38) | Return On Equity (0.65) |
The market value of CorMedix is measured differently than its book value, which is the value of CorMedix that is recorded on the company's balance sheet. Investors also form their own opinion of CorMedix's value that differs from its market value or its book value, called intrinsic value, which is CorMedix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CorMedix's market value can be influenced by many factors that don't directly affect CorMedix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CorMedix's value and its price as these two are different measures arrived at by different means. Investors typically determine if CorMedix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CorMedix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.